Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study by Murto, T et al.
Breast cancer extent and survival among diabetic women in a Finnish nationwide 
cohort study 
Murto M1, Artama M2, Pukkala E3, Visvanathan K4, Murtola TJ1,5 
1. Tampere University Hospital, Department of Surgery, Tampere, Finland 
2. National Institute for Health and Welfare, Helsinki, Finland
3. University of Tampere, Faculty of Social Sciences, Tampere, Finland 
4. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA 
5. University of Tampere, School of Medicine, Tampere, Finland
ABSTRACT 
Breast cancer (BC) and diabetes are major health problems. We examined the association between 
diabetes and BC stage at diagnosis and subsequent survival in a Finnish cohort of female BC patients. All BC 
cases (N = 73,170) diagnosed in 1995-2013 with dates and causes of death were identified from the Finnish 
Cancer Registry.  Participation in organized mammography screening was obtained from Mass Inspection 
Registry. Information on diabetes diagnoses and background conditions recorded during 1995-2013 were 
obtained from national Care Register for Health Care and merged to data on medication use from the 
national Prescription Register. Logistic regression with adjustment for mammography screening and age at 
BC diagnosis was used to evaluate the risk of advanced stage BC at diagnosis. Cox regression was used to 
evaluate overall and BC survival. Analyses were adjusted for age, background conditions and 
mammography screening. Survival analyses were further adjusted for tumor extent, histology and primary 
treatment.  Of the cohort 11,676 (16.0 %) had diabetes.  Screening participation did not differ by diabetes. 
Compared to non-diabetic women, diabetics had more often locally advanced (OR 1.18; 95% CI 1.10-1.26) 
or metastatic BC at diagnosis (OR 1.30; 95% CI 1.18-1.43). During a median follow-up of 5.8 years after BC 
diagnosis 10,900 (14.9 %) women died of BC. Risk of BC death was higher among diabetic compared to non-
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diabetic women (HR 1.36, 95% CI 1.27-1.46). Risk of BC death increased with duration of diabetes. This 
supports diabetes as a risk factor for fatal breast cancer. 
 
 
  
  
INTRODUCTION 
 
Breast cancer (BC) and diabetes mellitus (DM) are two major health problems for women. Incidence of both 
conditions rises after middle-age. BC is the most common cancer among women worldwide (1). It is the 
leading cause of cancer death among women in less developed countries, and the second most frequent 
cause of cancer death in developed regions (1). Age-standardized BC incidence has been increasing steadily 
worldwide whilst mortality has been decreasing since the 1990s (1). Around the world number of diabetics 
has risen from 108 million in 1980 to 422 million in 2014 (2). Global prevalence in DM among adults over 18 
years of age is estimated to be 8,5% in 2014 (2).  
Several previous studies have evaluated the association between use of antidiabetic drug metformin and 
BC risk and survival; many studies have reported a risk reducing effect for metformin (3). However, role of 
the underlying DM is unclear. Previous studies (4, 5, 6, 7) have explored the association between BC risk 
and DM per se especially among postmenopausal women with type 2 DM (7,8).  It has been shown that BC 
patients with DM have also higher BC mortality (4, 5) and overall mortality. DM is often closely associated 
with obesity, hyperinsulinemia and hyperglycemia, inflammation which in turn may affect risk of BC 
progression (5,8). Few studies have been able to estimate simultaneously the risk associations with closely 
correlated conditions obesity, DM, hypertension and hypercholesterolemia. Further, the role of timing of 
DM diagnosis in BC prognosis is unclear. 
We compared the association between DM (defined as recorded diagnosis of DM or antidiabetic drug use) 
and BC stage and survival in a large nationwide cohort of BC cases from Finland with simultaneous 
evaluation of background hypertension, hypercholesterolemia, cardiovascular disease and obesity. 
 
  
  
MATERIALS AND METHODS 
 
Study cohort 
The study population included all newly diagnosed BC cases among women in Finland from 1995 to 2013. In 
total 78,023 cases were identified from the Finnish cancer registry which covers over 99% of cancer cases in 
Finland (9). The registry collects data by mandatory cancer diagnosis reports from all Finnish health care 
units and pathology laboratories. ICD-codes C50.1-C50.9 were used to identify BC cases. Information 
included diagnosis date, patient age, tumor extent (available for 85.6% of cases, categorized into three 
groups localized, locally advanced (axillary lymph node involvement) and metastatic, histology (99.9%) and 
primary treatment (99.6%) as well as the date and causes of death. Information on deaths was available up 
to the end of 2013. Deaths with ICD-10 codes C50.1-C50.9 registered as the primary cause of death were 
considered BC deaths. Hormone receptor status or tumor grade are not recorded by the registry, thus not 
available at this time. From the original study population, we excluded 349 men with BC and 4,504 women 
who were diagnosed with carcinoma in situ only or the date of later diagnosis of invasive cancer was 
missing. Thus, after exclusion of 4,853 BC cases due to missing information the final study cohort included 
73,170 women.   
Finland has a government-mandated, nationwide comprehensive mammography screening program which 
covers all Finnish women of age 50-69. Invitations for mammography are sent every two years. Screening 
program started in 1980s and has a 90.9% national coverage (9). We obtained data on the number of 
mammography screens for each participant by linking the study cohort to national Mass Inspection registry 
maintained by the National Institute of Health and Welfare. 
 
Information on diabetes and other background conditions 
  
Data on recorded diagnoses were gathered by linking the study cohort to the Finnish Care Register for 
Health Care which registers diagnoses from all in- and outpatient hospital visits and treatment periods 
during 1995-2013. Linkage was carried out using unique personal identification number which is given to 
every Finnish citizen either at birth or alternatively can be applied for after receiving permission for 
residency for at least a year. Diagnoses of DM, hypertension, dyslipidemia, obesity and coronary artery 
disease were identified using respective ICD-10 coding (Supplementary table 1). The registry does not cover 
diagnoses from primary health care visits. Linking these diagnoses with drugs used in hypertension and 
hypercholesterolemia this information was more comprehensive excluding obesity which has no specific 
medication. 
 
Information on medication use 
The study cohort was linked to prescription database of the Finnish Social Insurance Institution (SII) using 
personal identification number to obtain information on antidiabetic, antihypertensive and cholesterol-
lowering medication use during 1995-2013. As part of the national health insurance SII reimburses costs of 
medication purchases for drugs prescribed by a licensed physician. National health insurance and its 
compensation covers the whole Finnish population and all compensated medication purchases are 
recorded by the database. Over-the-counter purchases or drugs dispensed during hospital inpatient period 
are not covered by the prescription database. The information includes ATC-classification, date for each 
purchase, medication strength, package size and the number of refills. 
Antidiabetic drugs were identified based on ATC-codes (Supplementary table 2). Additionally, we identified 
drugs used in management of hypertension, dyslipidemia and hormonal therapy (tamoxifen, fulvestrant 
and aromatase inhibitors). All drugs for the above-mentioned indications are available in Finland only 
through physicians’ prescription, thus recorded by the prescription database. 
 
  
Statistical analysis 
Information on yearly drug purchases was combined with the information on recorded diagnoses from the 
Finnish Care Register for Health Care to obtain yearly status of DM, hypertension and dyslipidemia. 
Participant was considered to have these conditions from the first year they had a recorded diagnosis or 
medication purchase for the conditions. 
The study population was categorized into two categories as hypertensive (recorded diagnosis of 
hypertension or purchase of antihypertensive drugs), dyslipidemic (recorded diagnosis of dyslipidemia or 
purchase of cholesterol-lowering statin drugs), obese (recorded diagnosis) or having coronary artery 
disease (recorded diagnosis). DM (recorded diagnosis of DM or purchase of antidiabetic drugs was 
categorized separately by timing in relation to BC: whether DM had been diagnosed before or after BC. 
Exposure time for pre-diagnostic DM was evaluated as number of years since the first DM diagnosis or 
purchase of anti-DM drug between 1995 and year of BC diagnosis. For post-diagnostic DM, the exposure 
time was defined as number of years between DM diagnosis or drug purchase and the end of follow-up. 
Charlson Comorbidity Index was calculated using recorded ICD-10 diagnoses from in- and outpatient 
hospital visits from HILMO supplemented with medication usage data from the SII prescription database. 
The 2011 updated version of the index was used (10). 
We used logistic regression to evaluate odds ratios (ORs) and 95% confidence intervals (95% CIs) for having 
locally advanced or metastatic BC at diagnosis by pre-diagnostic DM. These analyses were adjusted for age 
and additionally for background conditions and number of mammography screening rounds attended. 
Risk of BC death (hazard ratio, HR) was evaluated using Cox regression model adjusted for age and tumor 
extent at diagnosis, tumor histology, screening participation, primary treatment (surgery vs. other 
treatment), Charlson Comorbidity Index and for any use of statins, antihypertensive drugs or hormonal 
therapy during the follow-up. Time metric was years and months since BC diagnosis. The follow-up 
continued until death or the common closing date of Dec 31,2013, whichever came first.  DM before BC 
diagnosis was analyzed as time-independent variable based on status and years of exposure between 1995 
  
and year of BC diagnosis. DM post-BC diagnosis was analyzed as time-dependent variable, where DM status 
and cumulative years of exposure were updated separately for each follow-up year based on yearly 
recorded diagnoses and medication purchases.  
Validity of proportional hazards assumption was tested by adding interaction term between time-
independent variables and follow-up time into Cox regression model. Subgroup analyses were performed 
by variables for which the interaction term was statistically significant.  
We used Fine and Gray competing risks regression analysis to compare risk of BC deaths with non-breast 
cancer deaths as the competing risk, as DM is a known risk factor for cardiovascular disease and deaths.  
Analyses were done using IBM SPSS Statistics version 24 (Chicago, IL, USA). STATA 14.0 was used for 
competing risk regression analyses.  
  
  
RESULTS 
 
Population characteristics 
During the median follow-up of 5.8 years after diagnosis a total 22,520 (30.8%) women died, of these 
10,900 (14.9%) due to BC. In total 2,465 women (3.2% of the cohort) had a recorded DM diagnosis; 279 
with type I DM, 2,219 with type II DM and 62 with other type of DM, including DM with complications. A 
total of 11,676 (16.0%) women had either a recorded DM diagnosis or purchases of anti-DM medication 
during the study period. Due to small number of women with DM I or other type of DM, all types of DM 
were analyzed as one group.  Mean mammography screening participation rate was 57.9%, with no 
significant difference by diabetes. 
Diabetic women were older at diagnosis and had more often also hypertension, hypercholesterolemia, 
obesity and cardiovascular disease compared to the non-diabetic group (Table 1). In the diabetic group, 
most of the patients (95.4%) were at postmenopausal age at diagnosis. No differences in mammography 
screening (median of four mammography screens before diagnosis), Charlson Comorbidity Index, tumor 
histology or primary treatment were observed compared to the non-diabetics. Diabetic women had slightly 
less hormonal therapy after BC diagnosis (34.5% vs 38.4%, p for difference < 0.001). 
 
Tumor stage at diagnosis by diabetes mellitus 
Compared to non-diabetic women, BC was more often locally advanced or metastatic in diabetic women 
(multivariable adjusted OR 1.26; 95% CI 1.18-1.35 for locally advanced and OR 1.59; 95% CI 1.44-1.75 for 
metastatic cancer) (Table 2). At separate analysis, the risk association was similar among postmenopausal 
women. The risk association was stronger in women who had diabetes for at least five years before BC 
diagnosis. 
 
  
Risk of breast cancer death by diabetes mellitus 
For diabetics diagnosed before BC diagnosis, the risk of breast cancer death was higher compared to non-
diabetics both in the age-adjusted (HR 1.18; 95% CI 1.10-1.27) and multivariable-adjusted analysis (HR 1.36; 
95% CI 1.27-1.46) (Table 3). Also overall mortality was higher in the diabetic group (Table 3). Overall 
mortality, but not BC-specific mortality increased even more in participants with at least five years of DM 
before BC diagnosis.  
Also DM after BC diagnosis was associated with increased risk of BC-specific death, albeit not as strongly as 
pre-diagnostic DM (HR 1.15; 95% CI 1.09-1.22) and deaths due to any cause (HR 1.32; 95% CI 1.28-1.37) 
(Table 3). Again, the risk increase for deaths due to any cause increased along with years of diabetes in a 
linear manner, whereas the risk increase for breast cancer deaths attenuated in long-term. 
 
Subgroup analyses 
In subgroup analyses DM both before and after BC diagnosis was associated with worse BC survival 
regardless of tumor extent at diagnosis (Table 4). Similarly, tumor histology did not modify the risk 
associations. 
The risk increase for BC death by diabetes after BC diagnosis was stronger in the youngest age-group (39 or 
younger) (p for difference by age group < 0.001). No clear effect modification by primary treatment or 
background conditions were observed (Table 4). 
The risk increase by prediagnostic DM was stronger in women with positive mammography screen; HR 
2.00; 95% CI (1.56-2.56, p for interaction = 0.004) but remained elevated also in the mammography screen 
negative group (table 4). 
 
Sensitivity analyses 
  
In competing risks regression analysis women with prediagnostic DM had significantly increased risk for BC 
death HR 1.18; 95% CI (1.09-1.28). Diabetes after BC diagnosis was not associated with increased BC death 
in competing risks regression analysis. However, the analysis was prone to immortal time bias as diabetes 
could not be analysed as time-dependent variable. 
In multivariable-adjusted analysis also Charlson Comorbidity Index was independent predictor of breast 
cancer death in multivariable-adjusted analysis (HR 1.04; 95% CI 1.03-1.05 per 1-point increase in the 
index).  
To account for possible bias by missing information on prevalent diabetes diagnosed before BC we 
performed the analysis including only cases diagnosed on year 2000 or later. This ensured that all cases had 
information on diabetes for a minimum of five years’ time before the diagnosis. The analysis included 
57,023 patients, of which 8,992 had diabetes either before or after breast cancer diagnosis. The results did 
not differ from the main analysis; multivariable adjusted HR for BC mortality by pre-diagnosis DM (HR 1.36, 
95% CI 1.25-1.47) and BC mortality by post-diagnosis diabetes (HR 1.18, 95% CI 1.10-1.26). 
 
 
 
  
  
DISCUSSION 
 
Breast cancer patients with DM had elevated risk for locally advanced and metastatic tumor extent despite 
identical participation to mammography screening compared to non-diabetic patients. The association got 
stronger in correlation with years since the first recorded DM diagnosis. Further, we found an association 
with increased BC mortality and overall mortality which also got stronger along with years of DM before BC 
diagnosis. DM after BC diagnosis was further associated with worse disease-specific survival, but the risk 
increase attenuated along with years of DM post-diagnosis.  
Our study supports few previous studies reporting that BC patients with DM present with more advanced 
stage at diagnosis (11, 12). Retrospective cohort study (13) of 38,407 BC patients reported that women with 
DM were 14 %-21% more likely to present with Stage II-Stage IV BC after adjustment for socioeconomic 
factors, age, screening participation and comorbidities. Erikson et al (14) also defined DM according to 
HbA1C levels in a small study of 185 BC patients. BC patients with DM had more advanced cancer stage at 
diagnosis. None of these studies took antidiabetic medication use into account. Thus, our study adds to 
these previous findings as our study population was larger, and our definition of DM, hypertension and 
dyslipidemia also included medication usage for these indications. 
Previous studies (15, 16) have been controversial on whether diabetic women participate less frequently in 
screening mammograms which might explain later stage cancer at diagnosis. However, in our study we 
observed more advanced stage BC among diabetics despite identical mammography screening history 
compared to non-diabetics. Thus, our findings suggest that stage difference by DM is not explained by 
differential screening participation. However, as diabetic patients are prone to be more obese than non-
diabetics, breast self-examination via palpation may be more unreliable. This may lead to delayed 
diagnosis. Thus obesity remains a possible confounding factor in analyses on breast cancer extent. 
Higher BC mortality has previously been reported in BC patients with DM (4, 5). We observed increased risk 
of BC death among diabetic women independent of tumor extent at diagnosis. Thus, our results suggest 
  
that the survival difference is not a consequence of differing tumor stage at diagnosis between diabetic and 
non-diabetic women. It has also been proposed that BC patients with DM are less likely to receive 
chemotherapy because of higher toxicity rates (17, 18), which is a possible mechanism behind the observed 
risk increase  
On the other hand, DM may have a direct effect on carcinogenesis and cancer progression. Hyperglycemia 
and hyperinsulinemia accelerate cancer cell proliferation and inhibition of apoptosis in vitro (5, 19). Also 
obesity, a condition closely associated with DM, has been linked with increased BC risk in women and 
worse overall prognosis (20). Obesity is associated with chronic inflammation (7), oxidative stress (21) and 
reduction of AMP-activated protein kinase (22). The mechanism is likely to be multifactorial.  
Strengths of this study are the large nationwide cohort of 73,170 female patients with background 
information of background conditions, screening, treatment and maximum follow-up of 18 years. Our data 
on recorded diagnoses of diabetes, hypertension and hypercholesterolemia was based on hospital 
contacts, but was complemented by detailed data on medication use, thus covering all participants with 
medical treatment for the conditions. The exception was obesity, for which medication use is marginal.       
Detailed information on timing of medication use and diagnoses allowed us to evaluate them on a yearly 
basis. Thus, we were able to estimate the role of timing of DM on BC stage and prognosis. 
The study limitations include missing information on hormone replacement therapy as it is not reimbursed 
by the SII and not recorded in the prescription registry. Hormone receptor status or tumor grade were also 
unavailable from the national registries. We had no direct record of BMI and it is assumed that obesity 
diagnosis recorded in health care registries represents the most morbid cases, underestimating true 
prevalence of obesity. Further, we had no information on socioeconomic status and life-style factors such 
as smoking, which may have caused confounding increasing the observed risk estimates. Low 
socioeconomic status has been associated with worse survival in many cancer types, but in BC the 
association is somewhat unclear (23, 24). Current smoking is associated with increased risk of breast cancer 
death (25). 
  
 
 
CONCLUSIONS 
Women with DM have more often advanced stage BC and the prognosis of the disease is poorer compared 
to non-diabetic women even after adjustment for disease extent and screening participation. We found 
that these findings are strongest if DM was diagnosed before BC diagnosis which confirms the risk 
relationship between long-term DM exposure and fatal BC. 
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Table 1. Characteristics of the study cohort of 73,170 female breast cancer (BC) patients diagnosed in 
Finland during 1995-2013. 
 Diabetes before BC diagnosis  
Characteristic Yes 
5,469 (7.5%) 
 
No. (%) 
 
No 
67,701 (92.5%) 
 
No. (%) 
 
Total 
73,170 (100%) 
 
No. (%) 
 
Deaths 
BC deaths 874 (16.0) 10,026 (14.8) 10,900 (14.9) 
non-BC deaths 1,576 (28.8) 10,044 (14.8) 11,620 (15.9) 
Age at BC diagnosis*† 
39 or younger 5 (0.1) 570 (0.8) 575 (0.8) 
40-55 207 (3.8) 8,311 (12.3) 8,518 (11.6) 
56 and older 5,257 (96.1) 58,820 (86.9) 64,077 (87.6) 
Mammography screening history 
Any; n(%) 2,560 (46.8) 39,829 (58.8) 42,359 (57.9) 
Tumor stage at diagnosis 
Localized 2,451 (44.8) 34,185 (50.5) 36,636 (50.1) 
Locally advanced 1,789 (32.7) 22,254 (32.9) 24,043 (32.9) 
Metastatic 641 (11.7) 5,484 (8.1) 6,125 (8.4) 
Unknown 588 (10.8) 5,778 (8.5) 6,366 (8.7) 
Tumor histology; n (%) 
Invasive ductal 4,075 (74.5) 50,973 (75.3) 55,042 (75.2) 
Invasive lobular 879 (16.1) 11,367(16.8) 12,246 (16.7) 
Other 504 (9.2) 5,310 (7.8) 5,814 (7.9) 
Unknown 11 (0.2) 51 (0.1) 62 (0.1) 
Primary treatment 
Curative-intent surgery 3,304 (60.4) 45,527 (67.2) 48,831 (66.7) 
Other/unknown 2,165 (39.6) 22,174 (32.8) 24,339 (33.3) 
Hormonal therapy* 
n (%) 1,660 (30.4) 26,004 (38.4) 27,664 (37.4) 
  
Co-morbidities 
Charlson Co-morbidity Index; median 
(IQR)‡ 
0 (0-1) 0 (0-0) 0 (0-1) 
Hypertension* 5,124 (93.7) 45,745 (67.6) 50,869 (69.5) 
Hypercholesterolemia* 3,448 (63.0) 21,993 (32.5) 25,446 (34.8) 
Obesity* 87 (1.6) 340 (0.5) 427 (0.6) 
Cardiovascular disease* 557 (10.2) 2,279 (3.4) 2,836 (3.9) 
* P for difference between diabetic and non-diabetic group < 0.001. Calculated with chi-square.  
† Age group categorized as pre-menopausal (younger than forty), menopausal (40-55) and post-
menopausal (56 or older)  
‡ Breast cancer diagnosis excluded from the calculation of the Charlson Co-morbidity Index  
Table 2. Breast cancer (BC) extent by diabetes mellitus status. Study cohort of 73,170 female breast cancer 
patients diagnosed in Finland during 1995-2013. 
Diabetes status Number of BC cases OR (95% CI)* 
Localized Locally 
advanced 
Metastatic Unknown Locally 
advanced BC 
BC with 
distant 
metastases 
All BC cases 36,636 24,043 6,125 6,366   
Non-diabetics 30,832 20,167 5,160 5,778 Ref Ref 
Diabetics 
before BC 
2,451 1,789 641 588 1.26  
(1.18-1.35) 
1.59  
(1.44-1.75) 
Years of diabetes 
before BC 
      
less than 5 1,333 939 316 258 1.19  
(1.09-1.30) 
1.41  
(1.24-1.61) 
5 or more 1,118 850 325 330 1.35  
(1.23-1.48) 
1.81  
(1.58-2.07) 
BC in age 56 or older 33,233 20,062 5,046 6,166   
Non-diabetics 27,607 16,441 4,152 5,164 Ref Ref 
Diabetics 
before BC 
2,382 1,694 609 572 1.24  
(1.16-1.33) 
1.52  
(1.37-1.68) 
Years of diabetes 
before BC 
      
less than 5 1,292 893 294 251 1.19  
(1.09-1.30) 
1.37  
(1.19-1.57) 
5 or more 1,090 801 315 321 1.30  
(1.19-1.43) 
1.70  
(1.48-1.95) 
 
 
* Calculated using logistic regression with adjustment for age, number of mammography screening rounds 
attended before the BC diagnosis, hypercholesterolemia, hypertension, coronary artery disease and obesity 
  
Table 3. Risk of breast cancer (BC) death and death due to any cause, by diabetes mellitus (DM) status. 
Cohort of 73,170 breast cancer patients diagnosed in Finland between 1995-2013. 
 
DM status BC deaths All-cause deaths 
Number 
of deaths 
HR (95% CI) for BCdeath Number 
of deaths 
HR (95% CI) for death 
Age-
adjusted 
Multivariable-
adjusted* 
Age-
adjusted 
Multivariable-
adjusted* 
DM before BC diagnosis 
No 10,026 Ref Ref 20,070 Ref Ref 
Yes 874 1.18 
(1.10-1.27) 
1.36 
(1.27-1.46) 
2,450 1.42 
(1.36-1.48) 
1.60 
(1.53-1.67) 
Years of diabetes 
before BC 
      
less than 5 478 1.15 
(1.05-1.27) 
1.32 
(1.20-1.45) 
1,272 1.33 
(1.25-1.40) 
1.45 
(1.40-1.57) 
5 or more 396 1.22 
(1.10-1.35) 
1.42 
(1.28-1.57) 
1,178 1.54 
(1.45-1.63) 
1.76 
(1.66-1.87) 
DM after BC diagnosis 
No 9,505 Ref Ref 18,628 Ref Ref 
Yes 1,395 1.21 
(1.15-1.28) 
1.15 
(1.09-1.22) 
3,892 1.37 
(1.32-1.42) 
1.32 
(1.28-1.37) 
Years of diabetes 
after BC 
      
less than 3 717 1.39 
(1.29-1.50) 
1.29 
(1.19-1.39) 
1,536 1.36 
(1.29-1.43) 
1.30 
(1.29-1.37) 
3 to 6 years 485 1.00 
(0.91-1.10) 
0.95 
(0.86-1.04) 
1,474 1.28 
(1.21-1.35) 
1.22 
(1.15-1.29) 
longer than 6 
years 
193 1.10 
(0.94-1.28) 
1.04 
(0.89-1.21) 
882 1.55 
(1.44-1.66) 
1.48 
(1.38-1.59) 
 
* Calculated using Cox regression with adjustment for age, number of mammography screening rounds 
attended before the BC diagnosis, tumor extent, histology, primary treatment, hypercholesterolemia, 
hypertension, obesity, Charlson comorbidity index and use of hormonal therapy after the diagnosis  
Table 4. Risk of breast cancer (BC) death by diabetes mellitus (DM) within subgroups stratified by 
background variables. Cohort of 73,170 breast cancer patients diagnosed in Finland between 1995-2013. 
 
BC baseline characteristics Risk of BC death 
DM before BC DM after BC 
HR (95% CI) HR (95% CI) 
Tumor stage at dg   
Localized 1.49 (1.26-1.76) 1.24 (1.10-1.40) 
Locally advanced 1.30 (1.15-1.46) 1.09 (1.00-1.19) 
Metastatic 1.31 (1.16-1.48) 1.15 (1.03-1.28) 
Tumor histology   
Ductal 1.40 (1.29-1.53) 1.15 (1.07-1.23) 
Lobular 1.29 (1.08-1.54) 1.11 (0.97-1.27) 
Other 1.17 (0.96-1.42) 1.15 (0.98-1.36) 
Age at dg*   
39 or younger .. 2.56 (1.24-5.27) 
40-55 1.14 (0.84-1.56) 1.33 (1.11-1.60) 
56 or older 1.34 (1.25-1.45) 1.15 (1.08-1.22) 
Year of diagnosis   
1995-2004 1.25 (1.13-1.38) 1.11 (1.03-1.19) 
2005-2013 1.34 (1.21-1.49) 1.22 (1.11-1.34) 
Primary treatment   
Curative-intent surgery 1.42 (1.28-1.58) 1.18 (1.09-1.27) 
Other 1.29 (1.17-1.42) 1.14 (1.05-1.23) 
DM before BC diagnosis  
No .. 1.17 (1.08-1.27) 
Mammography screening  
<4 1.53 (1.29-1.80) 1.14 (1.01-1.29) 
≥4 1.32 (1.22-1.43) 1.15 (1.08-1.22) 
Mammography screen positive*  
Yes 2.00 (1.56-2.56) 1.26 (1.06-1.50) 
No 1.32 (1.22-1.42) 1.14 (1.07-1.21) 
 
 
* P for interaction < 0.05. Calculated by adding interaction term between the stratified variable and 
diabetes status into multivariable-adjusted Cox regression model. 
